|
Prospective Trials of
Drug Resistance Testing
Viradapt
The Viradapt study was a randomized trial of genotyping versus standard
of care to guide the choice of salvage regimen in patients failing
antiretroviral therapy (plasma HIV-1 RNA levels >10,000 copies/mL
after at least 3 months of a PI-containing triple-therapy regimen)
(18). Patients in the genotyping arm
had a significantly greater reduction in plasma HIV-1 RNA at 6 months
as compared to patients in the control arm.
Similarly, patients in the genotyping arm were more likely than
patients in the control arm to achieve a plasma HIV-1 RNA levels
<200 copies/mL at 6 months. Follow-up of these patients indicated
that these benefits persisted out to week 48 for patients in the
genotyping arm.
Further analysis of a subset of patients in this study demonstrated
the importance of achieving adequate plasma levels of PI's for optimal
treatment response, even after taking into account the benefits
of genotypic drug resistance testing (19).
4/15/01
Copyright 2001
by HIV and Hepatitis.com. All Rights Reserved
|
